A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple oral doses of HS-10522 in healthy Chinese participants and Chinese participants with mild hypertension.

NCT Number	NCT07609875
Lead Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions	Healthy Adult, Hypertension
Enrollment	88 participants
Start Date	2026-06-01
Primary Completion	2027-01-20 (estimated)
Study Completion	2027-02-03 (estimated)
Updated on ClinicalTrials.gov	2026-05-27